Prognostic significance of c-erbB-2 and p53 expression in colorectal carcinoma

Abstract

Objective: Colorectal cancer is the fourth commonest form of cancer occurring worldwide. In order to recognize the prognosis in colorectal carcinoma, a lot of clinic and pathologic parameters such as; tumor size, microscopic type, microscopic grade, depth of invasion, lymph node involvement, invasion of vascular and perineural, tumor stage have been used. In this study, we aimed to compare expression of c-erbB-2, p53 and classical prognostic factors, and to investigate the correlation with prognosis. Methods: In our study, operation materials belonging to 50 colorectal cases were examined retrospectively. Results: Overall, 100 % of colorectal carcinomas had nuclear-staining for p53 protein and 78% of carcinomas cytoplasmic and membranous staining or the c-erbB-2 showing distribution in a heterogeneous fashion. p53 overexpression correlated with (p

Keywords

• Colorectal carcinoma, c-erbB-2, p53

Kolorektal kanserlerde c-erbB-2 ve p53 ekspresyonunun prognostik önemi

Abstract

Amaç: Kolorektal kanserler dünya genelinde 4. en sık görülen kanser tipidir. Kolorektal karsinomlarda prognozun belirlenmesi için; makroskobik çap, mikroskobik tip, mikroskobik derece, invazyon derinliği, lenf nodu tutulumu, vasküler ve perinöral invazyon, tümör evresi gibi birçok klinik ve patolojik parametre kullanılmaktadır. Çalışmamızda; c-erbB-2 ve p53 ekspresyonlarının klasik prognostik faktörler ile karşılaştırılarak ilişkinin araştırılması amaçlanmıştır. Yöntemler: Çalışmamızda 50 kolorektal karsinom olgusuna ait operasyon materyalleri geriye dönük olarak incelenmiştir. Bulgular: Hastaların %100\'ü p53 ile nükleer ve %78\'i c-erbB-2 ile sitoplazmik ve membranöz boyanma göstermiştir. p53 overekspresyonunun patolojik evre, lenf nodu metastazı, anjiolenfatik invazyon, tümör derece ve diferansiyasyonu ile anlamlı derecede (p

Keywords

• Kolorektal karsinom, c-erbB-2, p53

References

1. Boyle P, Langman JS. ABC of colorectal cancer: epide- miology. BMJ 2000;321:805-808.
2. TC Sağlık Bakanlığı Kanserle Savaş Dairesi Başkanlığı 2006-2008 yılları Türkiye Kanser İnsidansı, www.kan- ser.gov.tr.
3. Rosai J (ed). Gastrointestinal Tract in Houston M (ed). Rosai and Ackerman’s Surgical Pathology. China:Elsevier Inc, 2004:776-825.
4. Li Q, Wang D, Li J, et al. Clinicopathological and prog- nostic significance of HER-2/neu and VEGF expres- sion in colon carcinomas. BMC Cancer 2011; 11: 277
5. Zambeti GP, Levine AJ. A comparison of the biologi- cal activites of wild type and mutant p53. FASEB J 1993;7:855-865.
6. Weınberg RA. Tumor supressor genes. Scıence1991;254:1138-1146.
7. Bendardaf R, Lamlum H, Pyrhönen S. Prognostic and Predictive Molecular Markers in Colorectal Carcino- ma. Anticancer Res 2004; 24:2519-2530.
8. Mıtchell RN, Kumar V. Neoplasia. İn: Kumar V, Cotran RS, Robbins SL.(eds). Basic Pathology. Crawford JM, The Oral Cavity and Gastrointestinal Tract. İn: Kumar V, Cotran RS, Robbins SL.(eds). Basic Pathology. W.B.Saunders Company, Sixth Edition, Philedelphia, U.S.A. 1997;145-154, 508-511.

9. Hollstein M, Sidransky D, Vogelstein B, et al. P53 mu- tations in human cancers. Science 1991;253:49-53.
10. Golmohammadi R, Namazi MJ, Nikbakht M, et al. Characterization and Prognostic Value of Muta- tions in Exons 5 and 6 of the p53 Gene in Patients with Colorectal Cancers in Central Iran. Gut Liver 2013;7:295-302.
11. Vernimmen D, Gueders M, Pisvin S, et al. Different mechanisms are implicated in ERBB2 gene overex- pression in breast and in other cancers. Br J Cancer 2003; 89: 899-906.
12. Kavanagh DO, Chambers G, O’Grady L, et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009;9:1.
13. Demirbaş S, Sücüllü I, Yildirim S, et al. Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer. Turk J Gastroenterol 2006;17:13- 19.
14. Jesus EC, Matos D, Artigiani R, et al. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. Acta Cir Bras 2005; 20: 422-427.
15. Baiocchi G, Lopes A, Coudry RA, et al. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis 2009;24:1059-1068.
16. Essapen S, Thomas H, Green M, et al. The expres- sion and prognostic significance of HER-2 in colorec- tal cancer and its relationship with clinicopathological parameters. Int J Oncol 2004;24:241-248.
17. Osako T, Miyahara M, Uchino S, et al. Immunohisto- chemical study of c-erbB-2 protein in colorectal can- cer and the correlationwith patient survival. Oncology 1998; 55:548-555.
18. Diez M, Medrano M, Muguerza JM, et al. Influence of tumor localization on the prognostic value of p53 pro- tein in colorectal adenocarcinomas. Anticancer Res 2000;20:3907-3912.
19. Lustosa SA, Logullo A, Artigiani R, et al. Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarci- noma. Acta Cir Bras 2005;20:353-357.
20. Grizzle WE, Manne U, Weiss HL, et al. Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1). Int J Cancer 2002;97:403-409.
21. Zhao DP, Ding XW, Peng JP, et al. Prognostic signifi- cance of bcl-2 and p53 expression in colorectal carci- noma, J Zhejiang Univ Sci B 2005;6:1163-1169.
22. Watson NF, Madjd Z, Scrimegour D, et al. Evidence that the p53 negative /Bcl-2 positive phenotype is an independent indicator of good prognosis in colorec- tal cancer: a tissue microarray study of 460 patients. World J Surg Oncol 2005;3:47.
23. Ghita C, Vilcea ID, Dumıtrescu M, et al. The prognos- tic value of the immunohistochemical aspects of tu- mor suppressor genes p53, bcl-2, PTEN and nuclear proliferative antigen Ki-67 in resected colorectal carci- noma. Rom J Morphol Embryol 2012;53:549-556.
24. Rambau PF, Odida M, Wabinga H. p53 expression in colorectal carcinoma in relation to histopatho- logical features in Ugandan patients. Afr Health Sci 2008;8:234-238.